Bread Financial to Participate in the KBW Fintech Payments Conference GlobeNewswire November 06, 2025 COLUMBUS, Ohio, Nov. 06, 2025 (GLOBE NEWSWIRE) — Bread Financial(R) Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S consumers, today announced the company's participation in the KBW […]
Evaxion announces business update and third quarter 2025 financial results GlobeNewswire November 06, 2025 COPENHAGEN, Denmark, November 6, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology(TM) powered vaccines, provides business update and announces third quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion has seen tremendous progress
EDAP Reports Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One(R) Sales and U.S. Procedure Volumes 167% YoY Growth in Focal One System Placements 15% YoY Growth in U.S. Focal One HIFU Procedures Company to Host Conference Call
Kelly Reports Third-Quarter 2025 Earnings GlobeNewswire November 06, 2025 TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025. Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ(TM) and ReSPECT-LM, and future directions and needs GlobeNewswire November 06, 2025 HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”),
NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ:MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=175823&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
TSXV: PGZ | OTCQB: PGZFF | FRA: 2EU — Escacena South expands mineral rights to +10,000 ha — Escacena Project drilling continuing at Bravo target — Cármenes Project drilling continuing at Providencia target Pan Global Resources Inc. (“Pan Global” or the “Company”) (TSXV: PGZ) (OTCQB: PGZFF) (FRA: 2EU) is pleased to announce the identification of
First Gene Therapy Trial for Angelman Syndrome Orphan Drug Designation Granted for MVX-220 MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS.
Findings show how asset managers integrate sustainability factors into their investment processes Callan, a leading institutional investment consulting firm, announced the release of its 2025 Asset Manager Sustainable Investment Practices Study, highlighting asset manager responses to environmental, social, and governance questions in Callan's proprietary database. Compiling input from over 1,500 unique organizations, the study reveals
NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=175821&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or